

FDA says ADHD med Adderall is in short supply

October 13 2022



People with attention-deficit/hyperactivity disorder (ADHD) or

narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.

The [Adderall](#) and [Adderall IR](#) shortage is due to intermittent manufacturing delays at [Teva](#), one of the companies that produces the medication.

While other companies continue to produce these amphetamine mixed salts, they don't make enough to meet U.S. demand.

Adderall is FDA-approved for [ADHD](#) and [narcolepsy](#), a sleep disorder.

Until supply is restored, alternatives include the extended-release version of amphetamine mixed salts, the FDA said.

The FDA has posted [information](#) online on current manufacturers and available product strengths. It is monitoring the shortage and helping manufacturers get what they need to resolve it. The agency said it would continue to provide updates.

Patients should work with their doctors to determine their best treatment option, according to a news release from the FDA's Center for Drug Evaluation and Research.

More information: The U.S. Centers for Disease Control and Prevention has more on [ADHD](#).

Copyright © 2022 [HealthDay](#). All rights reserved.

Citation: FDA says ADHD med Adderall is in short supply (2022, October 13) retrieved 27 February 2023 from <https://medicalxpress.com/news/2022-10-fda-adhd-med-adderall-short.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.